|
GARRIDO, Marcelo
Proyecto
(2020)
|
|
Proyecto
(2020)
|
|
Proyecto
(2020)
|
|
Proyecto
(2019)
|
|
Proyecto
(2019)
|
|
Proyecto
(2018)
|
|
Proyecto
(2018)
|
|
Proyecto
(2018)
|
|
GARRIDO, Marcelo
Proyecto
(2018)
|
A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developing metastasis following nephrectomy
Hoffmann-La Roche (WO39210)
Proyecto
2017-2024
Coinvestigador(a)
|
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Archigen Biotech Limited (AGB002)
Proyecto
2017-2019
Coinvestigador(a)
|
|
Ramirez, Pablo
Proyecto
(2017)
|
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).
Astellas Pharma Global Development, Inc (APGD) (9785-CL-0335)
Proyecto
2016-2020
Coinvestigador(a)
|
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage
Hoffmann-La Roche (GO29438)
Proyecto
2016-2019
Coinvestigador(a)
|
|
Proyecto
(2016)
|
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Gilead Sciences (GS-US-296-1080)
Proyecto
2015-2018
Coinvestigador(a)
|
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of The Subcutaneous Administration Of Tanezumab (Pf-04383119) In Subjects With Cancer Pain Predominantly Due To Bone Metastasis Receiving Backgr
Pfizer (A4091061)
Proyecto
2015-2020
Coinvestigador(a)
|
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibi
Novartis Pharmaceuticals (CBYL719C2301)
Proyecto
2015-2018
Coinvestigador(a)
|
A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Canc
Hoffmann-La Roche (WO29522)
Proyecto
2015-2018
Coinvestigador(a)
|
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Car
Hoffmann-La Roche (GO29437)
Proyecto
2015-2018
Coinvestigador(a)
|
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stag
Hoffmann-La Roche (GO29436)
Proyecto
2015-2019
Coinvestigador(a)
|
A phase 1/2 Dose escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administration of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients with Selected CD38+ Hemetological Malignances
Sanofi (TED10893)
Proyecto
2010-2019
Coinvestigador(a)
|
Portal del Investigador
